Neurocrine Biosciences announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by Neurocrine Biosciences. “This compound is an important part of our muscarinic portfolio, which enters the clinic as a potential treatment for movement disorders,” said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “Selectively targeting M4 receptors could benefit a broad range of motor coordination disorders, including Parkinson’s disease tremor and dystonia.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
- Neurocrine price target raised to $150 from $140 at Citi
- Neurocrine price target raised to $164 from $154 at Canaccord
- Neurocrine price target raised to $216 from $200 at Oppenheimer
- Neurocrine price target raised to $169 from $150 at Barclays